"The U.S. Food and Drug Administration today approved Dotarem (gadoterate meglumine) for use in magnetic resonance imaging (MRI) of the brain, spine and associated tissues of patients ages 2 years and older.
Dotarem is a gadolinium-based"...
Anesthesia providers need to obtain the following information from patients prior to administration of anesthesia:
- Medications they are taking, including herbal supplements
- Drug allergies, including allergic reactions to anesthetic agents (including hepatic sensitivity)
- Any history of severe reactions to prior administration of anesthetic
- If the patient or a member of the patient's family has a history of malignant hyperthermia or if the patient has a history of Duchenne muscular dystrophy or other latent neuromuscular disease
Anesthesia providers should inform patients of the risks associated with SUPRANE (desflurane) :
- Post-operative nausea and vomiting and respiratory adverse effects including coughing.
- There is no information of the effects of SUPRANE (desflurane) following anesthesia on the ability to operate an automobile or other heavy machinery. However, patients should be advised that the ability to perform such tasks may be impaired after receiving anesthetic agents
Last reviewed on RxList: 4/27/2010
This monograph has been modified to include the generic and brand name in many instances.
Additional Suprane Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.